## **TREND Statement Checklist**

Paper Section/ Topic	Item	Descriptor	Reported?	
	No		V	Pg#
Title and Abst	ract			
Title and	1	Information on how unit were allocated to interventions	V	Abstract
Abstract		Structured abstract recommended	V	Abstract
		Information on target population or study sample	V	Abstract
Introduction				
Background	2	Scientific background and explanation of rationale	V	Introduction
		Theories used in designing behavioral interventions	V	Entroduction
Methods				
Participants	3	Eligibility criteria for participants, including criteria at different levels in		Subjects
		recruitment/sampling plan (e.g., cities, clinics, subjects)	V	10,000
		Method of recruitment (e.g., referral, self-selection), including the	. ,	Subjects
		sampling method if a systematic sampling plan was implemented	V	Fig la, b
		Recruitment setting	V	Subjects.
		Settings and locations where the data were collected	V	Subjects.
Interventions	4	Details of the interventions intended for each study condition and how		
		and when they were actually administered, specifically including:		
		Content: what was given?	·/	Methods
		<ul> <li>Delivery method: how was the content given?</li> </ul>	V	Methods
		<ul> <li>Unit of delivery: how were the subjects grouped during delivery?</li> </ul>	V	Methods
		Deliverer: who delivered the intervention?	\/	Methods
		Setting: where was the intervention delivered?	V	Methods
		o Exposure quantity and duration: how many sessions or episodes or	/	Methods
		events were intended to be delivered? How long were they intended to last?	./	Mettons
		Time span: how long was it intended to take to deliver the	./	Methody
		intervention to each unit?		Methods
Objectives	5	<ul> <li>Activities to increase compliance or adherence (e.g., incentives)</li> <li>Specific objectives and hypotheses</li> </ul>	1	Introducti
•	6		/	Introducto
Outcomes	0	<ul> <li>Clearly defined primary and secondary outcome measures</li> <li>Methods used to collect data and any methods used to enhance the</li> </ul>	<b></b>	1
		quality of measurements	<b>V</b>	Methody
		Information on validated instruments such as psychometric and biometric		Methods
		properties	V	Tionong
Sample Size	7	How sample size was determined and, when applicable, explanation of any	5.2	Subjects
		interim analyses and stopping rules	V	1000
Assignment	8	Unit of assignment (the unit being assigned to study condition, e.g.,	1	Subjects
Method		individual, group, community)	V	
		Method used to assign units to study conditions, including details of any	V	Subjects
		restriction (e.g., blocking, stratification, minimization)	V	ж
		Inclusion of aspects employed to help minimize potential bias induced due	<b></b>	Subjects
		to non-randomization (e.g., matching)		1

## **TREND Statement Checklist**

Blinding (masking)	9	<ul> <li>Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to study condition assignment; if so, statement regarding how the blinding was accomplished and how it was assessed.</li> </ul>	V	Not.
Unit of Analysis	10	<ul> <li>Description of the smallest unit that is being analyzed to assess intervention effects (e.g., individual, group, or community)</li> </ul>	V	Methods
		<ul> <li>If the unit of analysis differs from the unit of assignment, the analytical method used to account for this (e.g., adjusting the standard error estimates by the design effect or using multilevel analysis)</li> </ul>	V	Methols
Statistical Methods	11	Statistical methods used to compare study groups for primary methods outcome(s), including complex methods of correlated data	V	nettols
		<ul> <li>Statistical methods used for additional analyses, such as a subgroup analyses and adjusted analysis</li> </ul>	V	nerleds
		Methods for imputing missing data, if used	V	Not
		Statistical software or programs used	V	Methods
Results				
Participant flow	12	Flow of participants through each stage of the study: enrollment,		T
r ar cicipant nov		assignment, allocation, and intervention exposure, follow-up, analysis (a		
		diagram is strongly recommended)		
		<ul> <li>Enrollment: the numbers of participants screened for eligibility,</li> </ul>	,	Results
		found to be eligible or not eligible, declined to be enrolled, and enrolled in the study	/	Fal ab
		Assignment: the numbers of participants assigned to a study		Results
		condition	/	F31. ab
		Allocation and intervention exposure: the number of participants		Results
		assigned to each study condition and the number of participants	V	
		who received each intervention		Fg 1.ab
		o Follow-up: the number of participants who completed the follow-		Results
		up or did not complete the follow-up (i.e., lost to follow-up), by	V	
		study condition		Fig1 ah
		<ul> <li>Analysis: the number of participants included in or excluded from</li> </ul>	_	Results
		the main analysis, by study condition		Fielab
		<ul> <li>Description of protocol deviations from study as planned, along with</li> </ul>	V	Results
	1		I	
		reasons	-	
Recruitment	13	Dates defining the periods of recruitment and follow-up	1	Methods
Recruitment Baseline Data	13		√ √	Results Table 2
A STATE OF THE SALE AND RECOVERY OF	(2-109)	<ul> <li>Dates defining the periods of recruitment and follow-up</li> <li>Baseline demographic and clinical characteristics of participants in each</li> </ul>	<b>√</b>	Results
A STATE OF THE SALE AND RECOVERY OF	(2-109)	<ul> <li>Dates defining the periods of recruitment and follow-up</li> <li>Baseline demographic and clinical characteristics of participants in each study condition</li> <li>Baseline characteristics for each study condition relevant to specific disease prevention research</li> </ul>		Results Table 2 Results
A STATE OF THE SALE AND RECOVERY OF	(2-109)	<ul> <li>Dates defining the periods of recruitment and follow-up</li> <li>Baseline demographic and clinical characteristics of participants in each study condition</li> <li>Baseline characteristics for each study condition relevant to specific</li> </ul>	<b>√</b>	Results Table 2
A STATE OF THE SALE AND RECOVERY OF	(2-109)	<ul> <li>Dates defining the periods of recruitment and follow-up</li> <li>Baseline demographic and clinical characteristics of participants in each study condition</li> <li>Baseline characteristics for each study condition relevant to specific disease prevention research</li> <li>Baseline comparisons of those lost to follow-up and those retained, overall</li> </ul>	√ √	Results Table 2 Results Table 2
A STATE OF THE SALE AND RECOVERY OF	(2-109)	<ul> <li>Dates defining the periods of recruitment and follow-up</li> <li>Baseline demographic and clinical characteristics of participants in each study condition</li> <li>Baseline characteristics for each study condition relevant to specific disease prevention research</li> <li>Baseline comparisons of those lost to follow-up and those retained, overall and by study condition</li> <li>Comparison between study population at baseline and target population</li> </ul>	V V	Results Table 2 Results Table 2 Results Results
Baseline Data	14	<ul> <li>Dates defining the periods of recruitment and follow-up</li> <li>Baseline demographic and clinical characteristics of participants in each study condition</li> <li>Baseline characteristics for each study condition relevant to specific disease prevention research</li> <li>Baseline comparisons of those lost to follow-up and those retained, overall and by study condition</li> <li>Comparison between study population at baseline and target population of interest</li> </ul>	V V	Results Table 2 Results Table 2 Results

## **TREND Statement Checklist**

Numbers	16	<ul> <li>Number of participants (denominator) included in each analysis for each</li> </ul>	1	Results
analyzed	10	study condition, particularly when the denominators change for different	1	
		outcomes; statement of the results in absolute numbers when feasible		Fol a.h
		<ul> <li>Indication of whether the analysis strategy was "intention to treat" or, if</li> </ul>	./	ROUTS
		not, description of how non-compliers were treated in the analyses	V	
Outcomes and	17	For each primary and secondary outcome, a summary of results for each		Results
estimation		estimation study condition, and the estimated effect size and a confidence	/	Table 3.4
		interval to indicate the precision		[ant sr]
		Inclusion of null and negative findings	✓	Table 3, 1
		Inclusion of results from testing pre-specified causal pathways through	<i>y</i>	Resulty
		which the intervention was intended to operate, if any		Tabe 3.4
Ancillary	18	Summary of other analyses performed, including subgroup or restricted	,	Results
analyses		analyses, indicating which are pre-specified or exploratory	√	Keguity
Adverse events	19	Summary of all important adverse events or unintended effects in each		Results
			/	KE74611)
		study condition (including summary measures, effect size estimates, and	V	
		study condition (including summary measures, effect size estimates, and confidence intervals)		
DISCUSSION		, , , , , , , , , , , , , , , , , , , ,	V	
DISCUSSION Interpretation	20	confidence intervals)		
- The second of	20	confidence intervals)		Disussion
DISCUSSION Interpretation	20	<ul> <li>confidence intervals)</li> <li>Interpretation of the results, taking into account study hypotheses,</li> </ul>		Disussion
- The second of	20	<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> </ul>		
The same of the sa	20	Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study		
The same of the sa	20	<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> <li>Discussion of results taking into account the mechanism by which the</li> </ul>		
The same of the sa	20	<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> <li>Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative</li> </ul>		Dowsir
The same of the sa	20	<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> <li>Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations</li> </ul>	✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓	Dowsir
The same of the sa	20	<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> <li>Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations</li> <li>Discussion of the success of and barriers to implementing the intervention,</li> </ul>	✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓	Discussion Discussion
Interpretation	20	<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> <li>Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations</li> <li>Discussion of the success of and barriers to implementing the intervention, fidelity of implementation</li> </ul>	√ √ √	Discussion Discussion
Interpretation		<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> <li>Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations</li> <li>Discussion of the success of and barriers to implementing the intervention, fidelity of implementation</li> <li>Discussion of research, programmatic, or policy implications</li> <li>Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of</li> </ul>	√ √ √	Discussion Discussion Discussion
Interpretation		<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> <li>Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations</li> <li>Discussion of the success of and barriers to implementing the intervention, fidelity of implementation</li> <li>Discussion of research, programmatic, or policy implications</li> <li>Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in</li> </ul>	✓ ✓ ✓ ✓ ✓ ✓	Discussion Discussion Discussion
The same of the sa		<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> <li>Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations</li> <li>Discussion of the success of and barriers to implementing the intervention, fidelity of implementation</li> <li>Discussion of research, programmatic, or policy implications</li> <li>Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of</li> </ul>	✓ ✓ ✓ ✓ ✓ ✓	Dismission Dismission Dismission Dismission Dismission Dismission
Interpretation		<ul> <li>Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study</li> <li>Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations</li> <li>Discussion of the success of and barriers to implementing the intervention, fidelity of implementation</li> <li>Discussion of research, programmatic, or policy implications</li> <li>Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in</li> </ul>	✓ ✓ ✓ ✓ ✓ ✓	Discussion Discussion Discussion

From: Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. American Journal of Public Health, 94, 361-366. For more information, visit: <a href="http://www.cdc.gov/trendstatement/">http://www.cdc.gov/trendstatement/</a>